Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab

S. J. Bakri, Jose S Pulido, C. A. McCannel, D. O. Hodge, N. Diehl, J. Hillemeier

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Purpose: To assess the intraocular pressure (IOP) changes, within the first 30 min after intravitreal injection of 0.1 ml (4 mg) triamcinolone, 0.09 ml (0.3 mg) pegaptanib, and 0.05 ml (1.25 mg) bevacizumab. Methods: Records of patients who received intravitreal triamcinolone, pegaptanib, and bevacizumab and who had their IOP measured post-injection were reviewed. Results: A total of 212 injections were performed (76 bevacizumab in 63 patients, 42 triamcinolone in 41 patients, 94 pegaptanib in 74 patients). At 10 min, over 87% of eyes receiving each drug had an IOP of less than 35 mmHg. Three of the 42 eyes receiving intravitreal triamcinolone were treated with IOP-lowering drops for pressures of 44, 46, and 60 mmHg. No patients treated with intravitreal bevacizumab or pegaptanib received IOP-lowering drops. The number of eyes in each injection group that had an IOP rise >10 mmHg within 30 min after injection was 27.6% of eyes receiving bevacizumab, 33.3% of eyes receiving triamcinolone, and 36.2% of eyes receiving pegaptanib. At 10 min, eyes with glaucoma were less likely to have an IOP

Original languageEnglish (US)
Pages (from-to)181-185
Number of pages5
JournalEye
Volume23
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Triamcinolone
Intravitreal Injections
Intraocular Pressure
Injections
Bevacizumab
pegaptanib
Glaucoma
Pressure
Pharmaceutical Preparations

Keywords

  • Bevacizumab
  • Eye
  • Intraocular pressure
  • Intravitreal
  • Pegaptanib
  • Triamcinolone

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. / Bakri, S. J.; Pulido, Jose S; McCannel, C. A.; Hodge, D. O.; Diehl, N.; Hillemeier, J.

In: Eye, Vol. 23, No. 1, 01.2009, p. 181-185.

Research output: Contribution to journalArticle

Bakri, S. J. ; Pulido, Jose S ; McCannel, C. A. ; Hodge, D. O. ; Diehl, N. ; Hillemeier, J. / Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. In: Eye. 2009 ; Vol. 23, No. 1. pp. 181-185.
@article{09f629cf22cd43159c63051590a9d6d0,
title = "Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab",
abstract = "Purpose: To assess the intraocular pressure (IOP) changes, within the first 30 min after intravitreal injection of 0.1 ml (4 mg) triamcinolone, 0.09 ml (0.3 mg) pegaptanib, and 0.05 ml (1.25 mg) bevacizumab. Methods: Records of patients who received intravitreal triamcinolone, pegaptanib, and bevacizumab and who had their IOP measured post-injection were reviewed. Results: A total of 212 injections were performed (76 bevacizumab in 63 patients, 42 triamcinolone in 41 patients, 94 pegaptanib in 74 patients). At 10 min, over 87{\%} of eyes receiving each drug had an IOP of less than 35 mmHg. Three of the 42 eyes receiving intravitreal triamcinolone were treated with IOP-lowering drops for pressures of 44, 46, and 60 mmHg. No patients treated with intravitreal bevacizumab or pegaptanib received IOP-lowering drops. The number of eyes in each injection group that had an IOP rise >10 mmHg within 30 min after injection was 27.6{\%} of eyes receiving bevacizumab, 33.3{\%} of eyes receiving triamcinolone, and 36.2{\%} of eyes receiving pegaptanib. At 10 min, eyes with glaucoma were less likely to have an IOP",
keywords = "Bevacizumab, Eye, Intraocular pressure, Intravitreal, Pegaptanib, Triamcinolone",
author = "Bakri, {S. J.} and Pulido, {Jose S} and McCannel, {C. A.} and Hodge, {D. O.} and N. Diehl and J. Hillemeier",
year = "2009",
month = "1",
doi = "10.1038/sj.eye.6702938",
language = "English (US)",
volume = "23",
pages = "181--185",
journal = "Eye (Basingstoke)",
issn = "0950-222X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab

AU - Bakri, S. J.

AU - Pulido, Jose S

AU - McCannel, C. A.

AU - Hodge, D. O.

AU - Diehl, N.

AU - Hillemeier, J.

PY - 2009/1

Y1 - 2009/1

N2 - Purpose: To assess the intraocular pressure (IOP) changes, within the first 30 min after intravitreal injection of 0.1 ml (4 mg) triamcinolone, 0.09 ml (0.3 mg) pegaptanib, and 0.05 ml (1.25 mg) bevacizumab. Methods: Records of patients who received intravitreal triamcinolone, pegaptanib, and bevacizumab and who had their IOP measured post-injection were reviewed. Results: A total of 212 injections were performed (76 bevacizumab in 63 patients, 42 triamcinolone in 41 patients, 94 pegaptanib in 74 patients). At 10 min, over 87% of eyes receiving each drug had an IOP of less than 35 mmHg. Three of the 42 eyes receiving intravitreal triamcinolone were treated with IOP-lowering drops for pressures of 44, 46, and 60 mmHg. No patients treated with intravitreal bevacizumab or pegaptanib received IOP-lowering drops. The number of eyes in each injection group that had an IOP rise >10 mmHg within 30 min after injection was 27.6% of eyes receiving bevacizumab, 33.3% of eyes receiving triamcinolone, and 36.2% of eyes receiving pegaptanib. At 10 min, eyes with glaucoma were less likely to have an IOP

AB - Purpose: To assess the intraocular pressure (IOP) changes, within the first 30 min after intravitreal injection of 0.1 ml (4 mg) triamcinolone, 0.09 ml (0.3 mg) pegaptanib, and 0.05 ml (1.25 mg) bevacizumab. Methods: Records of patients who received intravitreal triamcinolone, pegaptanib, and bevacizumab and who had their IOP measured post-injection were reviewed. Results: A total of 212 injections were performed (76 bevacizumab in 63 patients, 42 triamcinolone in 41 patients, 94 pegaptanib in 74 patients). At 10 min, over 87% of eyes receiving each drug had an IOP of less than 35 mmHg. Three of the 42 eyes receiving intravitreal triamcinolone were treated with IOP-lowering drops for pressures of 44, 46, and 60 mmHg. No patients treated with intravitreal bevacizumab or pegaptanib received IOP-lowering drops. The number of eyes in each injection group that had an IOP rise >10 mmHg within 30 min after injection was 27.6% of eyes receiving bevacizumab, 33.3% of eyes receiving triamcinolone, and 36.2% of eyes receiving pegaptanib. At 10 min, eyes with glaucoma were less likely to have an IOP

KW - Bevacizumab

KW - Eye

KW - Intraocular pressure

KW - Intravitreal

KW - Pegaptanib

KW - Triamcinolone

UR - http://www.scopus.com/inward/record.url?scp=58249105827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58249105827&partnerID=8YFLogxK

U2 - 10.1038/sj.eye.6702938

DO - 10.1038/sj.eye.6702938

M3 - Article

C2 - 17693999

AN - SCOPUS:58249105827

VL - 23

SP - 181

EP - 185

JO - Eye (Basingstoke)

JF - Eye (Basingstoke)

SN - 0950-222X

IS - 1

ER -